Risk of XXXX and Cardiac Events in Medically Treated Asymptomatic Carotid Stenosis.

@entity1 @entity64 @entity63 @entity299 @entity453 @entity543 @entity204 @entity385
BACKGROUND: The risk of @entity64 in @entity1 with 50% or more asymptomatic @entity543 (ACS) on intensive medical treatment is low. Hence, the optimal treatment of ACS remains controversial at this point of time. AIM: We assessed the risk of @entity385 ( @entity385 ) and @entity299 in @entity1 with 50% or more ACS on intensive medical treatment. METHODS: All @entity1 with @entity385 /minor @entity64 (National Institutes of Health @entity64 Scale score  <=5) who had undergone vessel imaging as part of their evaluation and @entity1 with @entity453 who had undergone vessel imaging before cardiac intervention were screened for the presence of asymptomatic @entity543 . The risk of @entity385 / @entity64 , @entity299 , and vascular deaths were evaluated. RESULTS: Of 1,800 @entity1 , 92 @entity1 (.05%) had ACS having 50% to 99% stenosis; 63 had @entity385 /minor @entity64 , and 29 had @entity453 , of whom 7 @entity1 had bilateral ACS, thus constituting 99 study units of ACS. The mean follow-up was 34.7  months (range 3-120  months). Two @entity1 developed @entity63 events on the side ipsilateral to the ACS and 9 @entity1 developed @entity299 during the follow-up. The average annual event rate for cerebral @entity63 events was .93% (95% confidence interval [CI], .11-3.37), 4.21% (95% CI, 1.92-7.98) for @entity299 , and 3.27% (95% CI, 1.31-6.74) for @entity204 . CONCLUSIONS: Although the risk of @entity64 in @entity1 with ACS is low, acute coronary events and vascular deaths were significant. This highlights the importance of intensive risk factor modification to reduce adverse cardiovascular events in ACS rather than revascularization of the @entity543 .
